Stretton C, Evans A, Hundal HS. Cellular depletion of atypical PKC is associated with enhanced insulin sensitivity and glucose uptake in L6 rat skeletal muscle cells. Am J Physiol Endocrinol Metab 299: E402-E412, 2010. First published June 8, 2010; doi:10.1152/ajpendo.00171.2010.-Atypical protein kinase C (aPKC) isoforms ( and ) have been implicated in the control of insulin-stimulated glucose uptake in adipose and skeletal muscle, but their precise role in this process remains unclear, especially in light of accumulating evidence showing that, in response to numerous stimuli, including insulin and lipids such as ceramide, activation of aPKCs acts to negatively regulate key insulin-signaling molecules, such as insulin receptor substrate-1 (IRS-1) and protein kinase B (PKB)/ cAMP-dependent PKC (Akt). In this study, we have depleted PKC in L6 skeletal muscle cells using RNA interference and assessed the effect this has upon insulin action. Muscle cells did not express detectable amounts of PKC. Depletion of PKC (Ͼ95%) had no significant effect on the expression of proteins participating in insulin signaling [i.e., insulin receptor, IRS-1, phosphatidylinositol 3-kinase (PI 3-kinase), PKB, or phosphate and tensin homolog deleted on chromosome 10] or those involved in glucose transport [Akt substrate of 160 kDa, glucose transporter (GLUT)1, or GLUT4]. However, PKC-depleted muscle cells exhibited greater activation of PKB/Akt and phosphorylation of its downstream target glycogen synthase kinase 3, in the basal state and displayed greater responsiveness to submaximal doses of insulin with respect to p85-PI 3-kinase/IRS-1 association and PKB activation. The increase in basal and insulininduced signaling resulted in an associated enhancement of basal and insulin-stimulated glucose transport, both of which were inhibited by the PI 3-kinase inhibitor wortmannin. Additionally, like RNAimediated depletion of PKC, overexpression of a dominant-negative mutant of PKC induced a similar insulin-sensitizing effect on PKB activation. Our findings indicate that aPKCs are likely to play an important role in restraining proximal insulin signaling events but appear dispensable with respect to insulin-stimulated glucose uptake in cultured L6 muscle cells. protein kinase C; glucose uptake; insulin receptor substrate 1; ribonucleic acid interference; protein kinase B/adenosine 3=,5=-cyclic monophosphate-associated kinase SKELETAL MUSCLE REPRESENTS an important site for insulinmediated glucose disposal and defects in insulin-stimulated glucose uptake in this tissue are linked strongly with insulin resistance and metabolic diseases such as type II diabetes. Although the functional importance of key molecular players of the classical insulin signaling pathway, such as insulin receptor substrate-1 (IRS-1), phosphatidylinositol 3-kinase (PI 3-kinase), and protein kinase B {PKB [aka cAMP-dependent kinase (Akt)]} are well characterized with respect to the stimulation of glucose transport, the role played by others in this process remains less well defined. Binding of insulin to its receptor induces activation of the insulin receptor kinase, which tyrosine phosphorylates members of the IRS family thereby promoting their interaction with and subsequent activation of adapter proteins, such as PI 3-kinase (33). Activated PI 3-kinase generates 3-phosphatidylinositol derivatives (e.g., PIP3) in the plasma membrane, which then serve to activate downstream targets (37). Both 3-phosphoinositide-dependent protein kinase 1 (PDK1) and PKB/Akt are recruited to the plasma membrane by the stimulus-induced rise in PIP3. Once there, PKB is phosphorylated by PDK1 and mammalian target of rapamycin complex 2 at Thr 308 and Ser 473 , respectively (1, 11, 36). Activated PKB can then target a number of downstream targets, including glycogen synthase kinase 3 (GSK3) and Akt substrate of 160 kDa (AS160; TBC1D4) (18, 34). Phosphorylation of GSK3 results in its inactivation, which permits the stimulation of glycogen synthase, thereby facilitating storage of glucose as glycogen (18). Phosphorylation of AS160 at multiple sites is thought to be important in disabling its Rab-GAP activity, which then alleviates its inhibitory effect on target Rab proteins that support translocation of intracellular glucose transporter 4 (GLUT4) vesicles to the cell surface (32).
SKELETAL MUSCLE REPRESENTS an important site for insulinmediated glucose disposal and defects in insulin-stimulated glucose uptake in this tissue are linked strongly with insulin resistance and metabolic diseases such as type II diabetes. Although the functional importance of key molecular players of the classical insulin signaling pathway, such as insulin receptor substrate-1 (IRS-1), phosphatidylinositol 3-kinase (PI 3-kinase), and protein kinase B {PKB [aka cAMP-dependent kinase (Akt)]} are well characterized with respect to the stimulation of glucose transport, the role played by others in this process remains less well defined. Binding of insulin to its receptor induces activation of the insulin receptor kinase, which tyrosine phosphorylates members of the IRS family thereby promoting their interaction with and subsequent activation of adapter proteins, such as PI 3-kinase (33) . Activated PI 3-kinase generates 3-phosphatidylinositol derivatives (e.g., PIP3) in the plasma membrane, which then serve to activate downstream targets (37) . Both 3-phosphoinositide-dependent protein kinase 1 (PDK1) and PKB/Akt are recruited to the plasma membrane by the stimulus-induced rise in PIP3. Once there, PKB is phosphorylated by PDK1 and mammalian target of rapamycin complex 2 at Thr 308 and Ser 473 , respectively (1, 11, 36) . Activated PKB can then target a number of downstream targets, including glycogen synthase kinase 3 (GSK3) and Akt substrate of 160 kDa (AS160; TBC1D4) (18, 34) . Phosphorylation of GSK3 results in its inactivation, which permits the stimulation of glycogen synthase, thereby facilitating storage of glucose as glycogen (18) . Phosphorylation of AS160 at multiple sites is thought to be important in disabling its Rab-GAP activity, which then alleviates its inhibitory effect on target Rab proteins that support translocation of intracellular glucose transporter 4 (GLUT4) vesicles to the cell surface (32) .
PDK1 also phosphorylates and activates members of the atypical protein kinase C (aPKC) family (19) . The aPKC family comprises two isoforms, PKC and PKC/, which are ubiquitously expressed and evolutionarily conserved throughout many different species and have been implicated in numerous biological processes, including cell polarity (16) , inflammation (35) , cellular proliferation (5), differentiation (12) , and cytoskeleton regulation (10) . In addition to these functions, there is considerable evidence implicating aPKCs in the control of glucose homeostasis. However, despite several reports demonstrating that inhibition of aPKC activity impairs insulinstimulated glucose uptake (see review in Ref. 14 and references therein), the exact underlying mechanism by which they regulate this important physiological event is largely unresolved. Moreover, it is noteworthy that the involvement of aPKCs in the insulin-dependent regulation of glucose transport is not a universally accepted phenomenon. This issue remains contentious given that some reports have been unable to demonstrate any effect of a reduction in aPKC activity/expression on glucose transport (39, 43) , whereas others have shown that aPKCs can physically interact with IRS-1 and PKB and that by doing so negatively regulate IRS-1 (21, 30) and PKBdirected signaling (13, 17, 22) .
In the current study, we have investigated the impact of depleting aPKC activity either via stable knockdown using RNAi or expression of a dominant-negative aPKC on insulin signaling and glucose transport in skeletal muscle cells. We show that stable silencing of PKC expression by Ͼ95% or overexpression of a dominant-negative aPKC in cultured muscle cells induced a significant increase in insulin sensitivity, judged on the basis of enhanced phosphorylation of key signaling proteins in response to submaximal insulin concentrations. Our data also indicate that, in L6 skeletal muscle cells, aPKC activity is dispensable with respect to insulin-stimulated glucose uptake. P]ATP were purchased from PerkinElmer Life Sciences (Waltham, MA). Anti-aPKC, anti-phosphate, and tensin homolog deleted on chromosome 10 (PTEN), -GLUT1, and -GLUT4 antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-IR, -IRS-1, and -PI 3-kinase-p85 antibodies were obtained from Millipore (Bedford, MA). Anti-actin antibody was purchased from SigmaAldrich. Anti-AS160 antibody was a gift from Professor Grahame Hardie (University of Dundee). Antibody against the ␣ 1-subunit of the Na ϩ -K ϩ -ATPase was obtained from the Developmental Studies Hybridoma Bank, University of Iowa. All other antibodies used were purchased from Cell Signaling Technologies (Beverley, MA). Protein G-Sepharose was purchased from GE Healthcare (Little Chalfont, UK). Crosstide, peptide inhibitor of cAMP-dependent protein kinase (PKI), and ATP were a gift from Dr. Nicholas Leslie, University of Dundee. Oligos were purchased from the University of Dundee Oligo Synthesis Service.
MATERIALS AND METHODS

Materials
Cell culture and generation of stable cell lines. L6 rat skeletal muscle cells were grown as described previously (15) in ␣-MEM containing 2% (vol/vol) FBS and 1% (vol/vol) penicillin-streptomycin solution. Experiments were carried out at the myotube stage, and hormone treatments were carried out as indicated in the text and in the legends for Figs. 1-7. Human embryonic kidney (HEK) 293T and Ad293 cells were maintained in DMEM supplemented with 10% (vol/vol) FBS and 1% (vol/vol) penicillin-streptomycin solution. All cell lines were maintained at 37°C with 5% CO 2. Stable L6 knockdown cell lines were generated as described previously using the oligo sequences shown in Table 1 (20) . Stable cell lines were established using early passage cells and, once established, were only used for a maximum of five passages. Within this limited passage number, similar results were obtained. Stable expression of control and PKCtargeted hairpins had no discernible effects on the final differentiation state of the cells.
RNA extraction, cDNA synthesis, PCR, and quantitative PCR. RNA was extracted from cells using TriReagent (Sigma-Aldrich) according to the manufacturer's instructions. RNA was treated with DNase I (Promega, Madison, WI) and first-strand cDNA was synthesized from 1 g RNA using oligo(dT) 15 primers and Moloney murine leukemia virus reverse transcriptase (Promega). PCR amplification of PKC, PKC, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was carried out using the following primers: PKC sense 5=-CCATGATGCCAATGGACCAGTC-3=, PKC anti-sense 5=-TTCCCACTCTCCCTGGTGTTC-3=, PKC sense 5=-AGTAGATGA-CAAGAACGATGGTG -3=, PKC anti-sense 5=-TTGATCCCATCCA-CCCCATC-3=, GAPDH sense 5=-TGGAAAGCTGTGGCGTG-AT-3= and GAPDH anti-sense 5=-GCTTCACCACCTTCTTGAT-3=. Amplification was carried out using GoTaq DNA polymerase (Promega), and cycling conditions were as follows: initial denaturation 94°C for 2 min followed by 30 cycles (25 for GAPDH) of 94°C for 30 s, 55°C for 30 s, 72°C for 1 min followed by a final extension of 72°C for 5 min. PCR products were separated on a 1.5% agarose gel and visualized by staining with ethidium bromide.
Quantitative PCR was performed using an ABI Prism 7000 (Applied Biosystems, Foster City, CA) real-time thermocycler, SYBR Green kit (Sigma-Aldrich), and primers targeting PKC and GAPDH as a control. PCR conditions were as follows: initial denaturation 95°C for 2 min followed by 40 cycles of denaturation at 95°C for 15 s, annealing at 55°C for 15 s, and extension at 68°C for 30 s. Primer sequences used for PKC and GAPDH were the same as those above. The ratio of PKC mRNA expression vs. GAPDH mRNA expression was calculated using a method described previously (26) .
Generation of isoform-specific antibodies. Isoform-specific antibodies against PKC and PKC were generated for use in some of the experiments in this study. The peptides EKEAMNTRESGK, corresponding to residues 231-243 of rat PKC, and LKPVIDGVDGIK, corresponding to residues 230 -242 of rat PKC, were synthesized with the addition of an NH 2-terminal cysteine residue (Pepceuticals, Nottingham, UK). The peptides were conjugated via the cysteine thiol to keyhole limpet hemocyanin and injected in sheep for the production of anti-sera. The immunization schedule and affinity purification of the antibodies on phosphopeptide columns were carried out as previously described (38) .
Preparation of whole cell lysates and total cellular membranes, immunoprecipitation, and immunoblotting. L6 myotubes were incubated for the time and with the appropriate amount of effectors as described in the text and legends for Figs. 1-7. After treatment, cells were rinsed two times with ice-cold PBS and then lysed as described previously (15) . Total cell membranes were isolated from L6 myotubes as described previously (15) . Protein concentration in cell lysates and membranes was determined using the Bradford (9) method. Cell lysates and membranes were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes, and immunoblotted with primary antibodies against proteins of interest before incubation with the appropriate peroxidase-conjugated IgG antibodies. Proteins were detected using chemiluminescence involving exposure to autoradiographic film (15) . Immunoprecipitation was performed using protein G-Sepharose beads complexed to the appropriate antibody. The bead-antibody complexes were incubated with 500 g cell lysate, and immunoprecipitates were pelleted as described previously (15) and subjected to SDS-PAGE and immunoblotting as described above. Quantification of immunoblots was carried out using Image J (National Institutes of Health).
PKB activity assay. PKB␣ was immunoprecipitated as described above, and the final antibody-bead complexes were washed first in lysis buffer then in reaction buffer [50 mM Tris·HCl, pH 7.5, 0.1 mM EGTA, 0.1% (vol/vol) ␤-mercaptoethanol]. Beads were resuspended in reaction buffer containing 10 mM MgCl 2, 2.5 M PKI (TTYADFIASGRTGRRNAIHD), 0.1 mM [
32 P]ATP (200 cpm/ pmol), and 30 M crosstide (GRPRTSSFAEG) as a substrate. Assays were carried out for 30 min at 37°C with continuous agitation. The reaction mixture (40 l) was applied to p81 filter papers that were then washed in phosphoric acid. The incorporated radioactivity was measured by scintillation counting. Kinase (1 mU) activity was the amount of enzyme that catalyzed the phosphorylation of 1 pmol of substrate in 1 min.
2-DG uptake. 2-DG uptake was measured as described previously (15) . Briefly, L6 myotubes were incubated in the absence and presence of insulin at times and concentrations indicated in the legends for Figs. 1-7. Cells were washed three times with HEPES-buffered saline (140 mM NaCl, 20 mM HEPES, 5 mM KCl, 2.5 mM MgSO 4, 1 mM CaCl2, pH 7.4). 2-DG uptake was assayed by incubation with 10 M 2-deoxy-[
3 H]-D-glucose (1 Ci/ml) for 10 min as described previously (15) . Nonspecific binding was determined by quantifying cellassociated radioactivity in the presence of 10 M cytochalasin B. Radioactive medium was aspirated before washing adherent cells two times with 0.9% (wt/vol) ice-cold saline. Cells were subsequently lysed in 50 mM NaOH, and radioactivity was quantified using a Beckman LS 6000IC scintillation counter. Protein concentration in cell lysates was determined using the Bradford (9) method.
Preparation of recombinant adenovirus and cell treatment. Recombinant kinase-inactive PKC adenovirus was a gift from Dr. Adolfo Garcia-Ocana (University of Pittsburgh, Pittsburgh, PA). The PKC sequence contains a K281W mutation that renders the protein kinase inactive (40) . HEK Ad293 cells were incubated with 50 l virus in a minimal volume of serum-free medium for 2 h at 37°C and then complete cell culture medium was added. Cultures were incubated until ϳ70% of the cells were detached from the flask surface, and the medium containing recombinant adenovirus was collected and subjected to five freeze-thaw cycles. Cell debris was pelleted by centrifugation, and the supernatant containing virus was harvested. Virus was then passaged a second time in the same manner to obtain high-titre stocks. Viral stocks were titred using a standard plaque assay protocol on HEK Ad293 cells. Briefly, 80% confluent cells in six-well plates were inoculated with 200 l of increasing dilutions of virus and 300 l cell culture medium and incubated for 2 h at 37°C. Cells were then overlayed with a 1:1 mix of 2ϫ DMEM (containing 5% FBS) and 1.2% agarose. Plaques took ϳ5-7 days to develop and were visualized using 0.33% neutral red solution. Transduction of L6 skeletal muscle cells was carried out 48 h before experiments. Cells, in six-well plates, were incubated with 500 l serum-free medium containing 3.5 ϫ 10 7 plaque-forming units virus for 2 h at 37°C. Complete culture medium (1 ml) was added to each well, and incubation of the cells continued as normal.
Statistical analysis. Data analysis was performed using GraphPad Prism software and considered statistically significant at values of P Ͻ 0.05. Bands from immunoblots were quantified using ImageJ software.
RESULTS
PKC is the principal aPKC isoform expressed in L6 skeletal muscle cells.
L6 skeletal muscle cells were analyzed to determine which aPKC isoforms were expressed. RNA was extracted from both undifferentiated and differentiated cells as well as from rat brain and subjected to analysis by RT-PCR using isoform-specific primers (Fig. 1A) . Whereas PKC was readily detectable in both undifferentiated and differentiated L6 cells, PKC was not, even following PCR using an increased cycle number (data not shown). PKC was, however, detected in cDNA prepared from rat brain, whereas the isoform was not readily detectable in this tissue. Fig. 1 . Expression of atypical protein kinase C (aPKC) in L6 myotubes. A: RNA was prepared from undifferentiated myoblasts, differentiated myotubes, and rat brain tissue, cDNA was synthesized, and PCR was carried out using primers specific to PKC and PKC. Primers specific to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were also used as a loading control. Loading was as follows: Mb, cDNA from undifferentiated L6 myoblasts; Mt, cDNA from differentiated L6 myotubes; Br, rat brain cDNA. B: specific antibodies were generated against PKC and PKC as described in MATERIALS AND METHODS. Antibody specificity was confirmed by immunoblotting (IB) against immunoprecipitated (IP) recombinant glutathione-S-transferase (GST)-PKC and GST-PKC fusion proteins (lanes 1 and 2, respectively). Thirty micrograms of rat brain or lysate from differentiated L6 myotubes were probed with anti-PKC antibody (left, lanes 3 and 4, respectively). Anti-PKC antibody was used to probe total aPKC immunoprecipitates from 500 g rat brain or L6 myotubes (right, lanes 3 and 4, respectively).
These observations were then substantiated at the protein level using isoform-specific antibodies for PKC and PKC. Recombinant glutathione-S-transferase (GST)-PKC and GST-PKC fusion proteins were used to confirm the specificity of the antibodies. Anti-PKC antibody was immunoreactive against the GST-PKC fusion protein but not GST-PKC fusion protein. Likewise, anti-PKC antibody only detected the PKC fusion protein but not GST-PKC (Fig. 1B) . Consistent with the PKC mRNA analysis, a protein band of ϳ70 -80 kDa was readily detectable in rat brain lysate but was undetectable in lysates prepared from fully differentiated L6 myotubes (Fig. 1B, left) . The anti-PKC antibody was weakly immunoreactive with whole cell lysates prepared from L6 myotubes (data not shown), and, consequently, the antibody was used to immunoprecipitate PKC from rat brain and L6 myotubes before immunoblotting in an attempt to enhance the immunoreactive signal. Consistent with our mRNA data, this analysis revealed that PKC protein was readily detectable in immunoprecipitates from L6 myotubes but not in immunoprecipitates prepared from rat brain (Fig. 1B, right) . The mRNA and protein data presented in Fig. 1 indicate that PKC is the dominant aPKC isoform in the L6 skeletal muscle cells used in this study and that any expression of PKC is likely to be negligible.
Stable knockdown of PKC in L6 myotubes and its effect on protein components of the insulin signaling pathway.
Having established that only PKC was expressed in our L6 muscle cell line, four short-hairpin RNA (shRNA) sequences designed to target PKC were inserted in a lentiviral knockdown vector, and stable L6 cell lines expressing each hairpin were established. Expression of the empty lentiviral vector or one containing the control hairpin sequence had no significant effect on total aPKC expression levels as judged using a commercial pan aPKC antibody (Fig. 2A) . The four different PKC hairpins suppressed PKC expression by varying amounts. Of the four hairpins deployed, those denoted as sh1151 and sh1503 induced an almost complete ablation of total aPKC expression, although very small amounts were detectable following prolonged exposure of film (data not shown). Stable expression of hairpins targeting PKC had no discernible effect on total aPKC levels, consistent with the data presented above confirming that PKC is the dominant aPKC isoform in L6 skeletal muscle cells (data not shown). Analysis of PKC mRNA levels in the cell lines stably expressing the control hairpin and hairpins sh1151 and sh1503 was carried out using quantitative PCR to determine the level of PKC knockdown (Fig. 2B) . Stable expression of the sh1151 hairpin resulted in a decrease of 92% of PKC transcript (P Ͻ 0.001) compared with cells expressing the control hairpin, whereas sh1503 expression reduced PKC transcript by 97% (P Ͻ 0.001).
The effect of PKC knockdown mediated by these two hairpins on components of the insulin-signaling pathway was next examined. Whole cell lysates and total membranes were prepared from control cells and those harboring the sh1151 and sh1503 hairpins and subsequently used to determine the abundance of key proteins involved in insulin signaling or glucose transport by immunoblotting. There were no significant differences observed in total levels of insulin receptor ␤-subunit, PI 3-kinase-p85 subunit, PKB, PTEN, AS160, and IRS-1 relative to actin between the different muscle cell lines (Fig. 3A) . Likewise, we found no change in the total abundance of GLUT1 and GLUT4 glucose transporters relative to the ␣ 1 -subunit of Na ϩ -K ϩ -ATPase in total membrane preparations between the different cell lines (Fig. 3B ). These observations indicate that, in these muscle cells, a substantial loss of PKC expression has no discernable effect on the expression of key proteins implicated in insulin signaling and glucose transport.
Silencing PKC expression enhances insulin sensitivity of l6 myotubes. Because muscle cells containing the sh1151 and sh1503 hairpins were not at variance with respect to expression of the signaling proteins of interest, we subsequently assessed the effect of silencing PKC on insulin action in the sh1503 cell line. This line was chosen since it displayed the greatest reduction in PKC of the four cell lines initially established. However, it should be stressed that, in separate experiments, we confirmed that the sh1151 line also exhibited qualitatively similar responses with respect to measures of insulin action [see Supplemental Fig. S1 (Supplemental data for this article can be found on the American Journal of Physiology-Endocrinology and Metabolism web site.)]. Figure 4A shows the effect of silencing PKC in L6 myotubes on insulin-induced PKB phosphorylation over a range of insulin concentrations. Phosphorylation of PKB in the basal state was consistently seen to be enhanced in PKC-depleted cells (Fig. 4A, top) compared Thirty micrograms of cell lysates were analyzed by immunoblotting with a pan PKC/ antibody and an anti-actin antibody as a loading control. B: total RNA was extracted from the stable cell lines containing control, PKC (sh1151 and sh1503) hairpins. cDNA was synthesized, and relative PKC mRNA levels, as measured against GAPDH mRNA levels, were assessed by quantitative PCR. Each bar represents means Ϯ SE of 3 independent experiments. Relative mRNA levels of PKC in sh1151 and sh1503 were both found to be significantly lower compared with those in the control cells. *Significant change from the control hairpin value (P Ͻ 0.05).
with control cells. This increase in basal phosphorylation was more apparent under long autorad exposure conditions and could be suppressed to the level observed in control cells if the sh1503-L6 cells were incubated with the PI 3-kinase inhibitor wortmannin before cell lysis (Fig. 4B) . This latter observation implies that heightened upstream signaling in the PKC knockdown cells may account for the elevated basal PKB phosphorylation. Insulin-induced phosphorylation of PKB Ser 473 was also noticeably enhanced in the PKC knockdown cells. Intriguingly, submaximal insulin doses (5-30 nM) evoked phosphorylation of PKB that was similar or greater in magnitude to that observed in the control cells exposed to maximally effective insulin doses (i.e., 100 nM). Qualitatively similar enhancement in PKB phosphorylation at a submaximal insulin concentration was also observed in the sh1151 cell line, minimizing the possibility that this insulin sensitization of PKB phosphoryla- Fig. 3 . Effects of PKC silencing on expression of proteins involved in insulin signaling. Lysates (A) and total membranes (B) were prepared from stably transduced L6 myotubes, and 30 g (10 g membranes) protein were subjected to Western blotting using antibodies targeting insulin receptor ␤-subunit, phosphatidylinositol 3-kinase [PI 3-kinase (PI3K)]-p85 subunit, protein kinase B (PKB), cAMP-dependent PKB substrate of 160 kDa (AS160), phosphate and tensin homolog deleted on chromosome 10 (PTEN), insulin receptor substrate-1 (IRS-1), glucose transporter (GLUT)1, and GLUT4 as indicated. Membranes were also probed for actin or Na ϩ -K ϩ -ATPase ␣1-subunit as loading controls. Blots are representative of at least 3 independent experiments. Densitometry plots are presented as fold changes in protein expression vs. control cells, and means Ϯ SE of at least 3 independent experiments are shown. tion may represent a potential off-target effect of the hairpins used (see Supplemental Fig. S1 ).
To assess whether the increased sensitivity to insulin seen in the PKC knockdown cells translated to enhanced PKB activity, we assayed immunoprecipitable PKB activity in the basal state and after cell incubation with 10 nM insulin. Compared with control cells, basal PKB activity in PKC knockdown cells was ϳ4-fold higher (Fig. 4C) and was elevated by Ͼ40-fold following cell treatment with 10 nM insulin. In contrast, this insulin dose only elicited a 10-fold increase in kinase activity in control cells. These activity measurements correlate well with the relative changes in PKB phosphorylation seen in the two respective cell lines in response to an acute 10 nM insulin challenge (Fig. 4A ). In line with the increase in basal and insulin-induced PKB phosphorylation, we observed a similar pattern of change in the phosphorylation of GSK3 (Fig.  4D) , a physiological downstream target of PKB. In addition to GSK3, we also monitored the phosphorylation status of Thr 389 on p70S6 kinase (p70S6K), a target site for mammalian target of rapamycin (which itself is a target for PKB; see Ref. 25 ). Again, we observed enhanced basal phosphorylation of p70S6K and greater activation of this kinase at submaximal insulin doses compared with control cells (Fig. 4E) . Unlike PKB and GSK3, no further increment in p70S6K phosphorylation was observed at higher insulin doses, possibly because maximum phosphorylation of the kinase had been attained. Additionally, we also examined the phosphorylation status of p44/42 mitogen-activated protein kinase (MAPK) on Thr 202 /Tyr 204 (Fig. 4F) . The aPKCs have been implicated as components of the growth factor-stimulated p44/42 MAPK signaling cascade (6) . Consistent with a role for aPKC in activation of p44/42 MAPK, we observed decreased phosphorylation of this kinase in PKC knockdown cells compared with control cells, thus confirming suppression of aPKC activity in the PKC knockdown cell line.
We also assessed whether PKC depletion had any effects on the activation of other MAPKs, namely c-Jun NH 2 Fig. S2 ). Phosphorylation of JNK was undetectable in both cell lines at the insulin concentrations tested. Stimulation with 10 nM insulin also had no discernible effects on p38-MAPK phosphor- Fig. 4 . Effects of PKC silencing on PKB (Akt)-directed insulin signaling. Stably transduced L6 myotubes were serum-starved for 2 h before being incubated in the absence or presence of increasing doses of insulin for 10 min or alternatively incubated in the absence/presence of 100 nM wortmannin for 30 min. Cell lysates were harvested, and either 20 g protein were analyzed by immunoblotting with phospho-PKB Ser 473 (A) and actin (B) antibodies, or 500 g were subjected to immunoprecipitation using total PKB antibody and analysis of PKB activity using crosstide as substrate (C). Bars in C represent means Ϯ SE of at least 3 independent experiments. *P Ͻ 0.05, statistically significant differences vs. the untreated control value (*) and significant change from the control insulin-treated value ( †). Lysates prepared identically to those in A were also prepared and run for analysis of phospho-GSK3␣/␤-Ser 21/9 (D), phospho-p70S6K Thr 389 (E), and phospho-p44/p42 Thr 202 /Tyr 204 (F) with actin serving as a loading control. The blots shown in A, D, E, and F are representative and the bar graphs (means Ϯ SE) show quantification of densitometry data from at least 3 independent experiments. MAPK, mitogen-activated protein kinase. *P Ͻ 0.05, significant changes in signal intensity of the indicated bar from the control cells treated with the same dose of insulin. C: significant differences (P Ͻ 0.05) from the untreated control (*) and significant difference from the insulin-treated control ( †).
ylation compared with that observed in the basal state. Depletion of PKC had no effect on this.
Effects of PKC silencing on glucose uptake. Given the increase in basal and insulin-induced PKB activity, we investigated what impact this would have on a functional end point of insulin action. We therefore assessed glucose uptake in the control and sh1503 cell lines in the absence and presence of increasing doses of insulin. In the control cells, treatment with increasing doses of insulin provoked a corresponding dosedependent increase in 2-DG uptake, with maximum uptake (ϳ2-fold that of basal) being achieved in response to 100 nM insulin (Fig. 5A) . 2-DG uptake in untreated sh1503 cells was ϳ1.7-fold greater than that seen in the corresponding control cells. Stimulation with 10 nM insulin induced a further stimulation of 2-DG uptake (ϳ2.5-fold) that was only marginally increased by further rises in the insulin concentration (2.6-fold at 100 nM insulin), suggesting that the maximum level of stimulated transport achievable in the knockdown cells had been reached at much lower insulin doses than that seen in the control cells. Prior treatment of sh1503-containing muscle cells with wortmannin (PI 3-kinase inhibitor) attenuated the observed increase in basal glucose uptake, suggesting that this increase stems from heightened upstream signaling via the PI 3-kinase/PKB axis (Fig. 5B) .
Given that there is evidence to suggest that aPKCs may interact with and negatively regulate IRS-1-directed signaling (23), we subsequently assessed not only tyrosine phosphorylation of IRS-1 but also association of aPKC and the p85 subunit of PI 3-kinase with IRS-1 in control and in PKC knockdown cells in the absence and presence of insulin. IRS-1 was immunoprecipitated from cell cultures and immunoprecipitates probed with a pan-aPKC antibody, a pan-phosphotyrosine antibody, or one directed against p85 (Fig. 6 ). In the absence of insulin, we observed very modest association of aPKC or p85 with IRS-1 in control cells. However, incubation of control cells with insulin induced a significant increase in the association of both proteins with IRS-1 (Fig. 6) . As expected, PKC knockdown cells did not exhibit any detectable aPKC/IRS-1 association, although, relative to unstimulated control cells, we could detect more (ϳ3-fold) p85/IRS-1 association in unstimulated PKC knockdown cells. However, in response to a submaximal insulin challenge, we observed a much greater association of p85 with IRS-1 in the PKC knockdown cells, consistent with the idea that these cells are more responsive to insulin (Fig. 6 ). Similar changes in basal and insulin-induced p85/IRS-1 association were also noted in the sh1151 hairpin-containing L6 cell line (see Supplemental Figs. 1 and 2) . Analysis of whole cell lysates by immunoblotting with a pan phosphotyrosine antibody revealed a number of proteins that exhibited enhanced tyrosine phosphorylation in both the basal and insulin-stimulated states in sh1503 cells compared with control cells. These included proteins with molecular weights consistent with IRS-1, the ␤-subunit of insulin receptor, and Shc, a downstream target of IRS-1 (Supplemental Fig. S2) .
Expression of a dominant-negative (kinase-dead) aPKC in L6 muscle cells enhances PKB activation in response to
insulin. To substantiate the finding that an increase in insulin sensitivity associated with stable silencing of PKC expression in L6 myotubes was not an off-target response of the RNAi strategy used in this study, we assessed the effect of transiently overexpressing an adenoviral construct encoding a dominantnegative form of PKC on PKB activation. As anticipated, cells transduced with the adenovirus expressed substantially more total aPKC. Overexpression of the dominant-negative PKC was observed to partially inhibit the phosphorylation of p44/42 MAPK induced by higher insulin concentrations (Fig. 7) , as seen in the PKC knockdown cells, thus confirming the inhibition of endogenous aPKC activity using this method. Although very slightly increased, overexpression of the dominant-negative PKC did not invoke a significant increase in PKB Ser 473 phosphorylation under unstimulated conditions, possibly as a consequence of the transfection efficiency associated with this expression strategy. Nevertheless, as in our PKC knockdown cells, PKB phosphorylation was enhanced significantly at all insulin doses studied compared with the corresponding insulin concentrations used in mock (control) transfected cells (Fig. 7) .
DISCUSSION
aPKCs have long been implicated in the insulin-dependent regulation of glucose uptake in both adipocytes and muscle cells but, as yet, the exact nature of their involvement in this process remains poorly understood (see Ref. 14 for a review). Based on expression of dominant interfering aPKC isoforms and use of nonselective PKC inhibitors, it has been suggested that activation of aPKCs in response to insulin is essential for promoting GLUT4 translocation to the cell surface and for supporting the associated increase in glucose uptake (14) . However, somewhat paradoxically, activation of aPKCs by proinflammatory stimuli such as tumor necrosis factor-␣ (24), saturated fatty acids, and fatty acid-derived lipids such as ceramide (8, 29) is associated with marked suppression of both insulin signaling and glucose transport (27, 29) . This inhibition may be attributed to a stimulus-induced association of aPKCs with IRS-1 and PKB/Akt, which serves to negatively regulate function of these key signaling intermediates (7, 23, 28, 30) .
In an attempt to help clarify the role played by aPKCs in insulin action, we generated L6 muscle cells that exhibit stable depletion of PKC. Our initial pilot studies had focused on suppressing expression of the -isoform based on previous work by Sajan and coworkers (31) who had reported that this was the major aPKC isoform expressed in L6 myotubes. However, transduction of our L6 muscle cells with lentiviral particles carrying shRNA homologous to PKC had no detectable effect on total aPKC levels when assessed using a pan aPKC antibody (data not shown). Subsequent RNA analysis and use of isoform-specific antibodies revealed that the L6 cells used in this study expressed primarily PKC and not PKC. We are unable to suggest a reason for this discrepancy other than proposing that there may be clonal differences between the L6 skeletal muscle cell lines used in the two studies. However, notwithstanding this difference in aPKC isoform expression, our studies reveal that a substantial depletion of PKC results in enhanced insulin sensitivity as judged using PKB activation and insulin-stimulated glucose uptake as readouts. This finding runs counter to the suggestion [see review and references cited therein (14) ] that aPKCs are indispensible components of the mechanism underpinning the insulindependent stimulation of glucose uptake, at least in the cell model used in the current studies. In contrast, the observed increase in insulin sensitivity of PKC-depleted cells is consistent with the view that aPKCs may normally function to restrain IRS-1 and PKB-directed signaling. The notion that aPKCs can operate as part of an insulin signaling "brake" at the level of IRS-1 is not new. There is compelling evidence to suggest that, in response to insulin, aPKCs are able to associate with and serine phosphorylate IRS-1 both in vitro and in vivo without affecting overall IRS-1 expression levels (23, 30) . This interaction has been demonstrated 1) to occur transiently following insulin stimulation (41, 42) , 2) to be dependent on aPKC activity (30), 3) to correlate inversely with IRS-1 tyrosine phosphorylation (23, 41) , and 4) to decrease IRS-1-associated PI 3-kinase activity (21, 30) . Further investigations have identified IRS-1 Ser 318 as an aPKC target (23) . Intriguingly, although IRS-1 serine phosphorylation is normally regarded as being functionally repressive, phosphorylation of Ser 318 is suggested not to be (41) . Instead, Weigert and coworkers (41) have suggested that phosphorylation of this site by aPKC serves as an insulin attenuation signal and that mutation of this residue to an alanine results in not only sustained IRS-1 signaling but maintains insulin-stimulated glucose uptake at an elevated rate. It thus follows that depletion or Fig. 6 . Effects of insulin on aPKC and p85-PI 3-kinase association in PKCdepleted cells. Control and PKC-depleted L6 myotubes were serum-starved for 2 h and incubated in the absence/presence of 10 nM insulin for 10 min. IRS-1 was immunoprecipitated from each cell line, and the immunoprecipitate was subjected to immunoblotting with a pan antibody to phosphotyrosine, PKC/, anti-p85, or anti-IRS-1 as indicated. Blots are representative of at least 3 independent experiments, and bars represent means Ϯ SE. P Ͻ 0.05, significant difference from the untreated control bar (*) and significant difference from the insulin-treated control ( †).
inhibition of aPKCs will be "insulin enhancing," which is fully consistent with our observations.
In line with these studies, we find that acute insulin treatment induces association of aPKC with IRS-1 in control muscle cells, which, unsurprisingly, was not detected in muscle cells substantially depleted of PKC. Consistent with the idea that aPKC association with IRS-1 would normally restrain downstream insulin signaling, we find that not only total tyrosine phosphorylation of IRS-1 and p85 (PI 3-kinase) subunit association with IRS-1 but also activation of PKB, GSK3␣/␤, and p70S6K were all significantly enhanced in cells lacking PKC in response to a submaximal insulin dose compared with that seen in control cells. The increase in insulin sensitivity of muscle cells lacking aPKC may also partly help explain the heightened basal phosphorylation of PKB, GSK3, and p70S6K that was consistently displayed by these cells. Because cells were routinely serum deprived for 2 h before experimental use, it is conceivable that the heightened basal signaling in PKC-depleted cells may reflect the inability to fully repress stimulation of the IRS/PI 3-kinase/PKB axis during the 2-h serum withdrawal period. This possibility is supported by the observation that PKC-depleted cells have modestly more p85-IRS-1 complexes under unstimulated conditions and that the increase in both basal PKB phosphorylation and glucose uptake could be reduced to that seen in control cells if they were preincubated with the PI 3-kinase inhibitor wortmannin. An important consequence of the moderate elevation in basal PI 3-kinase activity in PKC-depleted cells is that it supports a near fourfold increase in PKB activity. It is noteworthy that we have previously shown that a very modest increase (3-fold) in PKB activity, brought about, for example, by overexpressing PKB␣ in L6 cells, is sufficient for eliciting a near-maximal activation of glucose transport (15) . Consequently, although treatment of PKC-depleted cells with insulin induces a robust increase in PKB activity (from 4-fold to ϳ46-fold), the associated increase in glucose uptake is only moderately enhanced further from 1.7-fold in unstimulated cells to 2.5-fold with 100 nM insulin. These findings thus indicate that, in aPKC-depleted cells, glucose uptake is close to being near-maximally activated in the absence of insulin. Calculation of ED 50 for the net increase in glucose transport elicited by insulin over that seen in the basal (unstimulated) conditions for the two cell lines (30.1 nM in control cells compared with 2.2 nM in the sh1503 cells) lends further support to the argument for increased insulin sensitivity in the PKC knockdown cells. The increase in glucose uptake cannot be attributed to changes in total glucose transporter expression, which remain unaltered in our PKC-depleted cells but is more likely a consequence of their increased surface expression brought about by the prevailing increase in basal PI 3-kinase/ PKB signaling. The finding that the increase in glucose uptake is fully repressed by prior incubation of muscle cells with wortmannin is fully consistent with this proposition.
Studies using RNAi techniques in 3T3-L1 adipocytes have suggested that depletion of aPKC has no discernible effects on insulin-stimulated glucose uptake (43) , whereas other groups have demonstrated that a similar depletion results in loss of insulin-stimulated glucose uptake (31) . Currently, we are un- Fig. 7 . Effects of dominant negative (DN)-PKC on PKB phosphorylation. L6 myoblasts were transduced with ϳ3.5 ϫ 10 7 plaque-forming units adenovirus expressing DN kinase-inactive PKC (Ad DN-PKC) and allowed to differentiate. Myotubes were serumstarved for 2 h and treated with increasing concentrations of insulin for 10 min. Cell lysates were immunoblotted using phospho-PKB Ser 473 , p44/42 MAPK Th r202 /Tyr 204 , and actin antibodies. The bar graph shows quantification of PKB phosphoblots relative to the actin (loading control) signal. Values are means Ϯ SE from at least 3 independent experiments. *P Ͻ 0.05, statistically significant differences from the control cells treated with the same dose of insulin.
able to offer a satisfactory explanation for this discrepancy in results but can only support suggestions put forward previously to explain similar discrepancies (31) , namely that variations in the introduction of small-interfering RNA/shRNA in the cells may have an impact on the results observed. Our reported levels of RNAi-mediated knockdown at both mRNA and protein levels are similar to that reported in other studies, so it is unlikely that differing levels of knockdown are at the root of the different responses observed. However, unlike the other studies in question, we measured the effects of RNAi-mediated knockdown of aPKCs in cells in which PKC was stably depleted as opposed to a transient knock down. It is possible that sustained depletion of aPKC in skeletal muscle cells may have effects additional or different from those observed when the protein is only transiently depleted. However, this is unlikely since inhibition of aPKC activity using a kinase-inactive PKC mutant also resulted in increased sensitivity toward insulin based on analysis of PKB Ser 473 phosphorylation. Given that PKC and PKC have been demonstrated to function interchangeably, the K281W mutation in PKC has been used widely to inhibit endogenous aPKC activity (4, 40) . It is noteworthy, therefore, that Bandyopadhyay et al. (2) also observe greater PKB phosphorylation following transient adenoviral overexpression of kinase-inactive aPKC in L6 myotubes, which is suggestive of an increase in upstream insulin signaling. However, unlike our PKC-depleted cells, overexpression of the kinase-inactive aPKC adenoviral construct in either muscle cells or adipocytes was associated with a marked reduction in insulin-stimulated glucose uptake (2, 3) . This inconsistency is unlikely, in our view, to be solely explained by the use of different methods (i.e., stable shRNA silencing of PKC vs. transient overexpression of kinase-inactive aPKC adenovirus), since transient overexpression of the kinase-inactive adenoviral construct in adipocytes has previously been reported by others to also have no detectable impact on insulin-stimulated glucose uptake (39) .
In summary, we have shown that stable depletion of PKC in L6 myotubes using a lentiviral shRNA approach results in enhanced insulin sensitivity of muscle cells. This finding is consistent with the idea that aPKCs constitute part of a mechanism that normally acts to negatively regulate IRS and PKB/ Akt-directed signaling in response to stimuli, such as insulin (21, 30) . The substantial depletion in aPKC expression did not impact significantly upon expression of key insulin-signaling proteins nor did it result in reduced insulin-stimulated glucose transport capacity. These findings indicate that, although important for maintaining the responsiveness and fidelity of insulin signaling, aPKCs appear dispensable with respect to insulin-stimulated glucose uptake in L6 myotubes.
